Trial · NCT03364738
Results by group59
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 59
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants Who Achieved Total Albumin-corrected Serum Calcium (ACSC) Values Greater Than or Equal to (>=) to the Range of 7.5 mg/dL (1.875 mmol/L) and Less Than or Equal to (<=) Upper Limit of Normal (ULN) at Week 24 | rhPTH(1-84) | 100 | percentage of participants | ||
| Percentage of Participants With Total ACSC Values >= to the Range of 7.5 mg/dL (1.875 mmol/L) and <=ULN at Week 52 (End-of-treatment [EOT]) | rhPTH(1-84) | 95.5 | 0.772 to 0.999 | percentage of participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | rhPTH(1-84) | Participants with TEAEs | 17 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs | rhPTH(1-84) | Participants with serious TEAEs | 4 | Participants | |
| Number of Participants With Clinically Significant Change in Clinical Laboratory Values | rhPTH(1-84) | 0 | Participants | ||
| Number of Participants With Clinically Significant Change in Vital Sign | rhPTH(1-84) | 0 | Participants | ||
| Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Parameters | rhPTH(1-84) | 0 | Participants | ||
| Number of Participants With Clinically Significant Change in Estimated Glomerular Filtration Rate (eGFR) Values | rhPTH(1-84) | 0 | Participants | ||
| Number of Participants With Clinically Significant Change in Serum Creatinine Value | rhPTH(1-84) | 0 | Participants | ||
| Number of Participants With Positive Anti-Parathyroid Hormone Antibodies at Week 24 | rhPTH(1-84) | 0 | Participants | ||
| Change From Baseline in Albumin Corrected Serum Calcium (ACSC) Concentration at Weeks 24 and 52 (EOT) | rhPTH(1-84) | Change at Week 24 | -0.024 | Standard Deviation 0.2065 | mmol/L |
| Change From Baseline in Albumin Corrected Serum Calcium (ACSC) Concentration at Weeks 24 and 52 (EOT) | rhPTH(1-84) | Change at Week 52 (EOT) | -0.076 | Standard Deviation 0.1497 | mmol/L |
| Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) | rhPTH(1-84) | Change at Week 4 | -0.167 | Standard Deviation 0.1816 | mmol/L |
| Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) | rhPTH(1-84) | Change at Week 8 | -0.124 | Standard Deviation 0.2252 | mmol/L |
| Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) | rhPTH(1-84) | Change at Week 16 | -0.107 | Standard Deviation 0.2583 | mmol/L |
| Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) | rhPTH(1-84) | Change at Week 24 | -0.160 | Standard Deviation 0.2303 | mmol/L |
| Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) | rhPTH(1-84) | Change at Week 32 | -0.089 | Standard Deviation 0.1809 | mmol/L |
| Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) | rhPTH(1-84) | Change at Week 40 | -0.121 | Standard Deviation 0.2542 | mmol/L |
| Change From Baseline in Serum Phosphate Concentration at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) | rhPTH(1-84) | Change at Week 52 (EOT) | -0.114 | Standard Deviation 0.2590 | mmol/L |
| Change From Baseline in ACSC-phosphate Product at Weeks 4, 8, 16, 24, 32, 40 and 52 (EOT) | rhPTH(1-84) | Change at Week 4 | -0.31 | Standard Deviation 0.462 | mmol^2/L^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03364738/results